DexCom (DXCM) Tops Q3 EPS by 27c, Revenues Beat; Lifts FY18 Revenue Outlook Above Consensus

Go back to DexCom (DXCM) Tops Q3 EPS by 27c, Revenues Beat; Lifts FY18 Revenue Outlook Above Consensus

DexCom (DXCM) PT Raised to $150 at Oppenheimer

November 7, 2018 9:35 AM EST

Oppenheimer analyst Steven Lichtman raised the price target on DexCom (NASDAQ: DXCM) to $150.00 (from $125.00) while maintaining a Outperform rating.

The analyst commented, "DXCM's 3Q18 sales of $267M (+45% cc) beat our/consensus' $241/$243M, led by strong outperformance in International and better... More

DexCom (DXCM) PT Raised to $170 at Stephens

November 7, 2018 8:34 AM EST

Stephens analyst Chris Cooley raised the price target on DexCom (NASDAQ: DXCM) to $170.00 (from $160.00) while maintaining a Overweight rating following the company's 3Q report. Sales were in-line with Stephens' well-above consensus revenue estimate.

DXCM appears well positioned to continue to deliver... More